Notice:
OncoSil™ is currently approved in the following jurisdictions:
- European Union
- United Kingdom
- Singapore
- Malaysia
- New Zealand
- Switzerland

OncoSilTM is our breakthrough† device
†The OncoSilTM device has been designated a breakthrough device in both the United States (FDA) and Europe (BSI)1,2.
REFERENCES 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. 2. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.
WB00-AU-0121